{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T08:28:17Z","timestamp":1783240097757,"version":"3.54.6"},"reference-count":85,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.euf.2020.10.010","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T21:12:00Z","timestamp":1604351520000},"page":"1143-1156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-1771","authenticated-orcid":false,"given":"Hadi","family":"Mostafaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Quhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza Sari","family":"Motlagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Lysenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakineh","family":"Hajebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2020.10.010_bib0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10555-019-09800-w","article-title":"It is not just the drugs that matter: the nocebo effect","volume":"38","author":"Wojtukiewicz","year":"2019","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.euf.2020.10.010_bib0010","first-page":"203","article-title":"The nocebo reaction","volume":"95","author":"Kennedy","year":"1961","journal-title":"Med World"},{"key":"10.1016\/j.euf.2020.10.010_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuron.2008.06.030","article-title":"New insights into the placebo and nocebo responses","volume":"59","author":"Enck","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.euf.2020.10.010_bib0020","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000490354","article-title":"Implications of placebo and nocebo effects for clinical practice: expert consensus","volume":"87","author":"Evers","year":"2018","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.euf.2020.10.010_bib0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.pharmtox.48.113006.094711","article-title":"Mechanisms of placebo and placebo-related effects across diseases and treatments","volume":"48","author":"Benedetti","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.euf.2020.10.010_bib0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5152\/eurasianjmed.2019.19139","article-title":"Silodosin has nocebo effect on sexual adverse effects: a randomized controlled trial","volume":"51","author":"Sertkaya","year":"2019","journal-title":"Eurasian J Med"},{"key":"10.1016\/j.euf.2020.10.010_bib0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/bs.irn.2018.02.005","article-title":"Nocebo effects: neurobiological mechanisms and strategies for prevention and optimizing treatment","volume":"138","author":"Kleine-Borgmann","year":"2018","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.euf.2020.10.010_bib0040","series-title":"Contemporary pharmacotherapy of overactive bladder","first-page":"27","article-title":"The placebo effect in overactive bladder syndrome","author":"Lozo","year":"2019"},{"key":"10.1016\/j.euf.2020.10.010_bib0045","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.eururo.2006.05.014","article-title":"The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms","volume":"50","author":"van Leeuwen","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0050","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrurol.2011.99","article-title":"The placebo effect in overactive bladder syndrome","volume":"8","author":"Mangera","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3727\/000000003783992955","article-title":"Placebo-induced analgesia: methodology, neurobiology, clinical use, and ethics","volume":"7","author":"Benedetti","year":"2003","journal-title":"Rev Analg"},{"key":"10.1016\/j.euf.2020.10.010_bib0060","doi-asserted-by":"crossref","first-page":"597","DOI":"10.21037\/tau.2017.03.90","article-title":"Drugs for the overactive bladder: are there differences in persistence and compliance?","volume":"6","author":"Andersson","year":"2017","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0065","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1464-410X.2008.07769.x","article-title":"A review of adherence to drug therapy in patients with overactive bladder","volume":"102","author":"Basra","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.10.010_bib0070","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.euf.2020.10.010_bib0075","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.euf.2020.10.010_bib0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00044011-200019020-00001","article-title":"Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms","volume":"19","author":"Chancellor","year":"2000","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.euf.2020.10.010_bib0085","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/11316580-000000000-00000","article-title":"Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials","volume":"32","author":"Rief","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.euf.2020.10.010_bib0090","first-page":"126","article-title":"Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group","volume":"21","author":"Justice","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.euf.2020.10.010_bib0095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cct.2007.06.005","article-title":"Who controls the placebo? Introducing a placebo quality checklist for pharmacological trials","volume":"29","author":"Brinkhaus","year":"2008","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.euf.2020.10.010_bib0100","series-title":"Experimenter effects in behavioral research","author":"Rosenthal","year":"1976"},{"key":"10.1016\/j.euf.2020.10.010_bib0105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/archinte.166.2.155","article-title":"Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects","volume":"166","author":"Rief","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.euf.2020.10.010_bib0110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2008.08.009","article-title":"Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD","volume":"19","author":"Papakostas","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.euf.2020.10.010_bib0115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fpsyt.2019.00407","article-title":"Placebo effect in the treatment of depression and anxiety","volume":"10","author":"Kirsch","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.euf.2020.10.010_bib0120","doi-asserted-by":"crossref","first-page":"10390","DOI":"10.1523\/JNEUROSCI.3458-05.2005","article-title":"Neurobiological mechanisms of the placebo effect","volume":"25","author":"Benedetti","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.euf.2020.10.010_bib0125","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neuroscience.2007.02.020","article-title":"When words are painful: unraveling the mechanisms of the nocebo effect","volume":"147","author":"Benedetti","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.euf.2020.10.010_bib0130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.pain.2008.02.006","article-title":"The role of learning in nocebo and placebo effects","volume":"136","author":"Colloca","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.euf.2020.10.010_bib0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/10810730150501413","article-title":"Presenting risk information a review of the effects of framing and other manipulations on patient outcomes","volume":"6","author":"Edwards","year":"2001","journal-title":"J Health Commun"},{"key":"10.1016\/j.euf.2020.10.010_bib0140","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/bs.irn.2018.07.033","article-title":"The role of patient\u2013practitioner relationships in placebo and nocebo phenomena","volume":"139","author":"Blasini","year":"2018","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.euf.2020.10.010_bib0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062599","article-title":"Are treatments more effective than placebos? A systematic review and meta-analysis","volume":"8","author":"Howick","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2020.10.010_bib0150","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","article-title":"Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder","volume":"81","author":"Abrams","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0155","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1442-2042.2006.01387.x","article-title":"Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome","volume":"13","author":"Abrams","year":"2006","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0160","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0165","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1464-410X.2008.07939.x","article-title":"Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial","volume":"102","author":"Cardozo","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.10.010_bib0170","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","article-title":"Randomized, double\u2010blind placebo\u2010and tolterodine\u2010controlled trial of the once\u2010daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.10.010_bib0175","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.eururo.2007.05.027","article-title":"Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg","volume":"52","author":"Chapple","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0180","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1185\/03007X226294","article-title":"Darifenacin treatment of patients \u2265 65 years with overactive bladder: results of a randomized, controlled, 12-week trial","volume":"23","author":"Chapple","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.euf.2020.10.010_bib0185","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bju.12678","article-title":"Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double\u2010blind, placebo\u2010controlled EIGHT trial","volume":"114","author":"Chapple","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.10.010_bib0190","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.curtheres.2009.11.001","article-title":"Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder","volume":"70","author":"Chu","year":"2009","journal-title":"Curr Ther Res"},{"key":"10.1016\/j.euf.2020.10.010_bib0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/luts.12152","article-title":"Efficacy and safety of gabapentin in comparison to solifenacin succinate in adult overactive bladder treatment","volume":"10","author":"Chua","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euf.2020.10.010_bib0200","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2006.10.005","article-title":"Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder","volume":"51","author":"Dmochowski","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0205","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.urology.2007.11.008","article-title":"Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study","volume":"71","author":"Dmochowski","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.euf.2020.10.010_bib0210","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.urology.2009.09.018","article-title":"Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder","volume":"75","author":"Dmochowski","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.euf.2020.10.010_bib0215","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s001929970003","article-title":"Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder","volume":"10","author":"Drutz","year":"1999","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.euf.2020.10.010_bib0220","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.juro.2013.08.027","article-title":"Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial","volume":"191","author":"DuBeau","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0225","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bju.12174","article-title":"Efficacy of fesoterodine compared with extended\u2010release tolterodine in men and women with overactive bladder","volume":"112","author":"Ginsberg","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.10.010_bib0230","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/nau.22504","article-title":"Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and\/or mixed urinary incontinence: A randomized, double-blind, placebo-controlled study","volume":"34","author":"Goldfischer","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2020.10.010_bib0235","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1442-2042.2011.02732.x","article-title":"Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double\u2010blind, placebo\u2010controlled trial","volume":"18","author":"Gotoh","year":"2011","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0240","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","article-title":"Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder","volume":"45","author":"Haab","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0245","first-page":"A146","article-title":"Efficacy of tadalafil in treatment of overactive bladder syndrome: a randomized controlled trial","volume":"21","author":"Hajebrahimi","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0250","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1185\/03007990802537122","article-title":"Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms","volume":"24","author":"Herschorn","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.euf.2020.10.010_bib0255","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1464-410X.2009.09086.x","article-title":"Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head\u2010to\u2010head placebo\u2010controlled trial","volume":"105","author":"Herschorn","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.10.010_bib0260","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.10.010_bib0265","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1464-410X.2003.04468.x","article-title":"Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo\u2010controlled trial","volume":"92","author":"Homma","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.10.010_bib0270","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1464-410X.2010.09640.x","article-title":"Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial","volume":"107","author":"Kaplan","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.10.010_bib0275","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/ijcp.12464","article-title":"Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER","volume":"68","author":"Kaplan","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euf.2020.10.010_bib0280","first-page":"43","article-title":"Effectiveness of combined high\u2013dosed trospium and solifenacin depending on severity of OAB symptoms in elderly men and women under cyclic therapy","volume":"67","author":"Kosilov","year":"2014","journal-title":"Cent Eur J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0285","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.aju.2015.07.003","article-title":"The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection","volume":"13","author":"Kosilov","year":"2015","journal-title":"Arab J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0290","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.archger.2015.06.006","article-title":"A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron","volume":"61","author":"Kosilov","year":"2015","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.euf.2020.10.010_bib0295","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.urols.2014.12.010","article-title":"Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials","volume":"26","author":"Kuo","year":"2015","journal-title":"Urol Sci"},{"key":"10.1016\/j.euf.2020.10.010_bib0300","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/nau.22645","article-title":"Results of a randomized, double\u2010blind, parallel\u2010group, placebo\u2010and active-controlled, multicenter study of mirabegron, a \u03b23\u2010adrenoceptor agonist, in patients with overactive bladder in Asia","volume":"34","author":"Kuo","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2020.10.010_bib0305","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/01.ju.0000148963.21096.5d","article-title":"Assessment of cognitive function of the elderly population: effects of darifenacin","volume":"173","author":"Lipton","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0310","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1046\/j.1532-5415.2001.49144.x","article-title":"The Tolterodine in the Elderly Study Group. Tolterodine: a safe and effective treatment for older patients with overactive bladder","volume":"49","author":"Malone\u2010Lee","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.euf.2020.10.010_bib0315","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/nau.20928","article-title":"Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder","volume":"30","author":"Marencak","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2020.10.010_bib0320","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2018.10.006","article-title":"Vibegron (RVT-901\/MK-4618\/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial","volume":"75","author":"Mitcheson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0325","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1464-410X.2006.06146.x","article-title":"Efficacy and tolerability of tolterodine extended\u2010release in continent patients with overactive bladder and nocturia","volume":"97","author":"Nitti","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.10.010_bib0330","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0335","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cct.2014.04.009","article-title":"Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial","volume":"38","author":"Orri","year":"2014","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.euf.2020.10.010_bib0340","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/nau.22808","article-title":"Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: results from the randomised, placebo-controlled shrink study","volume":"35","author":"Robinson","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2020.10.010_bib0345","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00192-009-0969-8","article-title":"Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome","volume":"20","author":"Sand","year":"2009","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.euf.2020.10.010_bib0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.08.005","article-title":"Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome","volume":"206","author":"Sand","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.euf.2020.10.010_bib0355","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ijcp.12540","article-title":"The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double\u2010blind, placebo\u2010controlled phase 2 study","volume":"69","author":"Song","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euf.2020.10.010_bib0360","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.juro.2007.05.058","article-title":"Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial","volume":"178","author":"Staskin","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0365","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.juro.2008.11.125","article-title":"Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study","volume":"181","author":"Staskin","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0370","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3810\/pgm.2009.09.2062","article-title":"Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial","volume":"121","author":"Toglia","year":"2009","journal-title":"Postgrad Med"},{"key":"10.1016\/j.euf.2020.10.010_bib0375","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.euf.2020.10.010_bib0380","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1742-1241.2009.02209.x","article-title":"Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient\u2010reported outcomes: results from VIBRANT\u2013a double\u2010blind, placebo\u2010controlled trial","volume":"63","author":"Vardy","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euf.2020.10.010_bib0385","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.eururo.2019.10.002","article-title":"Efficacy, safety, and tolerability of mirabegron in patients aged \u2265 65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)","volume":"77","author":"Wagg","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0390","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.juro.2012.11.067","article-title":"Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency","volume":"189","author":"Weiss","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0395","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1464-410X.2007.07031.x","article-title":"Randomized, double\u2010blind, placebo\u2010and propiverine\u2010controlled trial of the once\u2010daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder","volume":"100","author":"Yamaguchi","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.10.010_bib0400","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/iju.12372","article-title":"Efficacy and safety of once\u2010daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: a randomized double\u2010blind trial","volume":"21","author":"Yamaguchi","year":"2014","journal-title":"Int J Urol"},{"key":"10.1016\/j.euf.2020.10.010_bib0405","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomised, double\u2010blind, placebo\u2010controlled study of the \u03b23\u2010adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2020.10.010_bib0410","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/luts.12088","article-title":"Optimum dose of once\u2010daily oxybutynin patch in Japanese patients with overactive bladder: a randomized double\u2010blind trial versus placebo","volume":"8","author":"Yamaguchi","year":"2016","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euf.2020.10.010_bib0415","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/luts.12053","article-title":"Efficacy and safety of the selective \u03b23\u2010adrenoceptor agonist mirabegron in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled, dose-finding study","volume":"7","author":"Yamaguchi","year":"2015","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.euf.2020.10.010_bib0420","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","article-title":"Vibegron, a novel potent and selective \u03b23-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study","volume":"73","author":"Yoshida","year":"2018","journal-title":"Eur Urol"},{"issue":"6 Part 1","key":"10.1016\/j.euf.2020.10.010_bib0425","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1097\/01.ju.0000127742.73136.0c","article-title":"Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial","volume":"171","author":"Zinner","year":"2004","journal-title":"J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456920302947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456920302947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:52:28Z","timestamp":1762498348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456920302947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":85,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2405456920302947"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2020.10.010","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2020.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}